genedrive

🎆Congratulations to William Newman John H McDermott and the team at The University of Manchester and Manchester University NHS Foundation Trust on their nomination for STEM Research Project of the Year! 💊 1 in 500 babies carry a gene that causes permanent deafness when given gentamicin, an antibiotic commonly used in intensive care. Working with University of Manchester start-up company Genedrive Plc, Manchester researchers developed the world’s first, rapid bedside genetic test. The test was trialled in 751 babies in neonatal units in Manchester and Liverpool. The test takes just 25 minutes, compared with several days for conventional methods, allowing doctors to give an alternative antibiotic within the recommended hour to those babies carrying the gene. The technology could save the hearing of 180 babies in the UK every year, and save the NHS ~£5 million annually, by reducing the need for interventions such as cochlear implants. The test is now being rolled-out in all of the Neonatal Intensive Care Units in Greater Manchester, and the NHS is exploring how the technology can become part of routine clinical care across the UK. Winners will be announced on 28th November, we wish you all the best of luck! #GDR #POCT #pharmacogenomics #pharmacogenetics #diagnostics #medtech #pgxmovement #pointofcare #adversedrugreactions #antibiotic resistance

Two years on since the publication of the Pharmacogenomics to Avoid the Loss of Hearing (PALOH) study in JAMA Pediatrics, we're delighted to announce that the NIHR (National Institute for Health and Care Research) has awarded PALOH-UK. 🏥 This project will see the integration of rapid point of care genetic testing in neonatal intensive care units across the UK. ⏩ The system, developed and updated by genedrive, is capable of detecting the m.1555A>G variant in just 26 minutes. This gene change predisposes to hearing loss when babies are exposed to a commonly prescribed antibiotic (gentamicin - an aminoglycoside). 👶 Babies who carry the genetic change will receive alternative, but equally effective, antibiotic and therefore avoid aminoglycoside induced hearing loss. 📖 Sites in each of the four nations will receive the system, and we'll be addressing a series of evidence gaps outlined by NICE - National Institute for Health and Care Excellence as part of their Early Value Assessment (EVA). 👨⚕️ Over the course of the programme, thousands of babies will receive this testing as part of standard of care at 14 sites around the UK. The programme is a collaboration between The University of Manchester, Manchester University NHS Foundation Trust, genedrive and clinical sites around the UK. We're excited to be working with lots of new colleagues, and also very pleased to be bringing the old team back together - at MFT Research and Innovation. Links for more information in the comments 👇

Join Patrick Breen, Stacey Gardiner and Charlotte Corner at the UK Stroke Forum, at the ACC in Liverpool from 3rd to 5th December... To hear how our NICE recommended CYP2C19 ID Kit is being used guide antiplatelet therapy by informing clinicians of patients CYP2C19 metaboliser status and diplotype. Book your place: https://lnkd.in/eCsMrSA #GDR #POCT #Stroke #patientsafety #pointofcare #pharmacogenomics #pharmacogenetics #StrokeAwareness

🎆We are pleased to announce a successful funding award from the National Institute for Health and Care Research (NIHR) and the UK Government Office for Life Sciences (OLS) 💊 Following the NICE - National Institute for Health and Care Excellence EVA recommendation, the NIHR/OLS Real World Evidence Programme will enable the addressing of real-world evidence gaps and the potential subsequent provision of a full (non-conditional) recommendation by NICE to accelerate the widespread adoption and implementation into the NHS. The program will run for a maximum of 18 months, with revenue to Genedrive for the MT-RNR1 ID kit under the programme expected to be approximately £500,000. Read the RNS: https://lnkd.in/ezVZWe6N #GDR #POCT #pharmacogenomics #pharmacogenetics #diagnostics #medtech #pgxmovement #pointofcare #adversedrugreactions #antibiotic resistance

Two years on since the publication of the Pharmacogenomics to Avoid the Loss of Hearing (PALOH) study in JAMA Pediatrics, we're delighted to announce that the NIHR (National Institute for Health and Care Research) has awarded PALOH-UK. 🏥 This project will see the integration of rapid point of care genetic testing in neonatal intensive care units across the UK. ⏩ The system, developed and updated by genedrive, is capable of detecting the m.1555A>G variant in just 26 minutes. This gene change predisposes to hearing loss when babies are exposed to a commonly prescribed antibiotic (gentamicin - an aminoglycoside). 👶 Babies who carry the genetic change will receive alternative, but equally effective, antibiotic and therefore avoid aminoglycoside induced hearing loss. 📖 Sites in each of the four nations will receive the system, and we'll be addressing a series of evidence gaps outlined by NICE - National Institute for Health and Care Excellence as part of their Early Value Assessment (EVA). 👨⚕️ Over the course of the programme, thousands of babies will receive this testing as part of standard of care at 14 sites around the UK. The programme is a collaboration between The University of Manchester, Manchester University NHS Foundation Trust, genedrive and clinical sites around the UK. We're excited to be working with lots of new colleagues, and also very pleased to be bringing the old team back together - at MFT Research and Innovation. Links for more information in the comments 👇

👋 Welcome Khadra Mahmoud, Genedrive’s Senior QA/RA Officer! Khadra is working hard to ensure our products continue to comply with IVDR regulations. 😊 It’s great to have you on the team! #GDR #POCT #Pharmacogenetics #Pharmacogenomics #Diagnostics #genetictesting

⭐ This December, Genedrive are attending the UK Stroke Forum, at the ACC in Liverpool. Join us in the exhibition hall, where Dr John H McDermott, NIHR Doctorial Research Fellow from the University of Manchester will be speaking on how rapid pharmacogenetic testing is being used to guide antiplatelet therapy. ❗ Don’t forget to visit our stand E22 to discover how our innovative genetic testing products can guide antiplatelet therapy by informing clinicians of CYP2C19 metaboliser status. Book your place: https://lnkd.in/eCsMrSA #GDR #POCT #Stroke #patientsafety #pointofcare #pharmacogenomics #pharmacogenetics #StrokeAwareness

🎆Congratulations to William Newman John H McDermott and the team at The University of Manchester and Manchester University NHS Foundation Trust on their nomination for STEM Research Project of the Year! 💊 1 in 500 babies carry a gene that causes permanent deafness when given gentamicin, an antibiotic commonly used in intensive care. Working with University of Manchester start-up company Genedrive Plc, Manchester researchers developed the world’s first, rapid bedside genetic test. The test was trialled in 751 babies in neonatal units in Manchester and Liverpool. The test takes just 25 minutes, compared with several days for conventional methods, allowing doctors to give an alternative antibiotic within the recommended hour to those babies carrying the gene. The technology could save the hearing of 180 babies in the UK every year, and save the NHS ~£5 million annually, by reducing the need for interventions such as cochlear implants. The test is now being rolled-out in all of the Neonatal Intensive Care Units in Greater Manchester, and the NHS is exploring how the technology can become part of routine clinical care across the UK. Winners will be announced on 28th November, we wish you all the best of luck! #GDR #POCT #pharmacogenomics #pharmacogenetics #diagnostics #medtech #pgxmovement #pointofcare #adversedrugreactions #antibiotic resistance

It’s the final day at MEDICA - Leading International Trade Fair 2024 So if you are looking for innovative point-of-care diagnostic tests to add to your distribution portfolio, visit Andrew Burns and Jonathan Dale on the stand in hall 1, F09-1 #GDR #innovation #genomics #pharmacogenetics #diagnostics #precisionmedicine

TODAY Genedrive are exhibiting at the POCT-for-Scot Ltd Conference in Glasgow! Speak to Gino Miele, Patrick Breen and Stacey Gardiner on the stand to... 👂 Learn how our Genedrive MT-RNR1 ID Kit can reduce the risk of antibiotic induced hearing loss in NICU patients. 👩⚕️ Discover how the Genedrive CYP2C19 ID Kit can guide antiplatelet therapy in stroke patients #GDR #POCT #pharmacogenomics #pharmacogenetics #diagnostics